-
公开(公告)号:US20090124642A1
公开(公告)日:2009-05-14
申请号:US12229682
申请日:2008-08-25
申请人: Augusto Canavesi , Marco Villa , Ales Gavenda , Jiri Faustmann , Judith Aronhime , Ettore Gibatti , Alexandr Jegorov
发明人: Augusto Canavesi , Marco Villa , Ales Gavenda , Jiri Faustmann , Judith Aronhime , Ettore Gibatti , Alexandr Jegorov
IPC分类号: A61K31/517 , C07D239/94
CPC分类号: C07D239/94
摘要: The invention provides a novel crystalline form of Erlotinib HCl, processes for its preparation, and formulations thereof.
摘要翻译: 本发明提供了一种新型的埃罗替尼盐酸结晶形式,其制备方法及其制剂。
-
2.
公开(公告)号:US20100256392A1
公开(公告)日:2010-10-07
申请号:US12743568
申请日:2008-11-21
申请人: Ales Gavenda , Ettore Bigatti , Alexandr Jegorov , Augusto Canavesi , Pavel Vraspir , Judith Aronhime , Peter Lindsay MacDonald , Francesca Scarpitta , Marco Villa , Paolo Angioletti
发明人: Ales Gavenda , Ettore Bigatti , Alexandr Jegorov , Augusto Canavesi , Pavel Vraspir , Judith Aronhime , Peter Lindsay MacDonald , Francesca Scarpitta , Marco Villa , Paolo Angioletti
IPC分类号: C07D403/06
CPC分类号: C07D403/06
摘要: The present invention provides polymorphs of Sunitinib base and processes for preparation thereof.
摘要翻译: 本发明提供舒尼替尼碱基的多晶型物及其制备方法。
-
3.Amorphous Erlotinib, processes for the preparation thereof, and processes to prepare additional forms of Erlotinib 审中-公开
标题翻译: 无定形埃罗替尼,其制备方法和制备另外形式的厄洛替尼的方法公开(公告)号:US20090012295A1
公开(公告)日:2009-01-08
申请号:US12215251
申请日:2008-06-25
IPC分类号: C07D239/72
CPC分类号: C07D239/94
摘要: The present invention provides amorphous erlotinib, processes for the preparation thereof, and processes to prepare additional forms of erlotinib.
摘要翻译: 本发明提供无定形厄洛替尼,其制备方法和制备另外形式的厄洛替尼的方法。
-
公开(公告)号:US20090118297A1
公开(公告)日:2009-05-07
申请号:US12257338
申请日:2008-10-23
申请人: Ondrej SIMO , Jiri Filipcik , Alexandr Martaus , Alexandr Jegorov , Ales Gavenda , Judith Aronhime , Pavel Vraspir , Tamas Koltai , Jiri Faustmann , Roman Gabriel
发明人: Ondrej SIMO , Jiri Filipcik , Alexandr Martaus , Alexandr Jegorov , Ales Gavenda , Judith Aronhime , Pavel Vraspir , Tamas Koltai , Jiri Faustmann , Roman Gabriel
IPC分类号: A61K31/506 , C07D417/14
CPC分类号: C07D417/12
摘要: Provided is dasatinib, solvates thereof and their crystalline forms, methods for their preparation, and pharmaceutical compositions thereof.
摘要翻译: 提供达沙替尼,其溶剂合物及其结晶形式,其制备方法及其药物组合物。
-
5.Polymorphic forms of imatinib mesylate and processes for preparation of novel crystalline forms as well as amorphous and form alpha 有权
标题翻译: 甲磺酸伊马替尼的多晶型形式以及制备新型结晶形式以及无定型和形成α的方法公开(公告)号:US20090264438A1
公开(公告)日:2009-10-22
申请号:US12148492
申请日:2008-04-17
IPC分类号: C07D401/14 , A61K31/496
CPC分类号: C07D401/04
摘要: Solvates and crystalline forms of imatinib mesylate are described. Further, methods for preparing such solvates and crystalline forms of imatinib mesylate are described.
摘要翻译: 描述了甲磺酸伊马替尼的溶剂合物和结晶形式。 此外,描述了制备这种溶剂化物的方法和甲磺酸伊马替尼的结晶形式。
-
6.Polymorphic forms of imatinib mesylate and processes for preparation of novel crystalline forms as well as amorphous and form alpha 有权
标题翻译: 甲磺酸伊马替尼的多晶型形式以及制备新型结晶形式以及无定型和形成α的方法公开(公告)号:US20080090833A1
公开(公告)日:2008-04-17
申请号:US11796573
申请日:2007-04-27
IPC分类号: A61K31/497 , C07D239/20
CPC分类号: C07D401/04
摘要: Solvates and crystalline forms of imatinib mesylate are described. Further, methods for preparing such solvates and crystalline forms of imatinib mesylate are described.
摘要翻译: 描述了甲磺酸伊马替尼的溶剂合物和结晶形式。 此外,描述了制备这种溶剂化物的方法和甲磺酸伊马替尼的结晶形式。
-
公开(公告)号:US08618309B2
公开(公告)日:2013-12-31
申请号:US13055609
申请日:2009-07-23
IPC分类号: C07D209/12
CPC分类号: C07D403/06 , C07D209/12
摘要: Process for the preparation of sunitinib malate form I via sunitinib acetate and polymorphs of said intermediate.
-
公开(公告)号:US20110118477A1
公开(公告)日:2011-05-19
申请号:US13055609
申请日:2009-07-23
IPC分类号: C07D403/06
CPC分类号: C07D403/06 , C07D209/12
摘要: Process for the preparation of sunitinib malate form I via sunitinib acetate and polymorphs of said intermediate.
摘要翻译: 通过醋酸舒尼替尼和所述中间体的多晶型物制备苹果酸舒尼替尼形式I的方法。
-
9.POLYMORPHS OF SORAFENIB TOSYLATE AND SORAFENIB HEMI-TOSYLATE, AND PROCESSES FOR PREPARATION THEREOF 有权
标题翻译: 磺基苯甲酸酯和辛酰胺高聚物的多聚体及其制备方法公开(公告)号:US20090192200A1
公开(公告)日:2009-07-30
申请号:US12356004
申请日:2009-01-19
申请人: Ales Gavenda , Alexandr Jegorov , Pierluigi Rossetto , Peter Lindsay MacDonald , Augusto Canavesi
发明人: Ales Gavenda , Alexandr Jegorov , Pierluigi Rossetto , Peter Lindsay MacDonald , Augusto Canavesi
IPC分类号: A61K31/44 , C07D213/81
CPC分类号: C07D213/81
摘要: Provided are sorafenib hemi-tosylate, polymorphs thereof, polymorphs of sorafenib tosylate, preparation thereof and pharmaceutical compositions thereof.
摘要翻译: 提供索拉非尼半对甲苯磺酸酯,其多晶型物,索拉非尼甲苯磺酸盐的多晶型物,其制备方法和药物组合物。
-
10.Process for the preparation of crystalline forms A, B and pure crystalline form a of erlotinib HCI 审中-公开
标题翻译: 制备结晶形式A,B和纯结晶形式的埃洛替尼HCl的方法公开(公告)号:US20090131665A1
公开(公告)日:2009-05-21
申请号:US12229701
申请日:2008-08-25
IPC分类号: C07D239/94
CPC分类号: C07D239/94 , A61K9/0048 , A61K9/2013 , A61K9/2018 , A61K9/2054
摘要: The invention provides processes for preparing crystalline Forms A, B and pure crystalline Form A of Erlotinib hydrochloride.
摘要翻译: 本发明提供了制备盐酸埃罗替尼的结晶形式A,B和纯结晶形式A的方法。
-
-
-
-
-
-
-
-
-